Trials / Completed
CompletedNCT06244498
Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty
Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty: Retrospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 110 (actual)
- Sponsor
- Piotr Biega · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.
Detailed description
Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic acid injection | Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
- First posted
- 2024-02-06
- Last updated
- 2024-02-06
Locations
1 site across 1 country: Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06244498. Inclusion in this directory is not an endorsement.